V900339
Cytosine β-D-arabinofuranoside
Vetec™, reagent grade, 90%
Synonym(s):
(β-D-Arabinofuranosyl)cytosine, Ara-C, Arabinocytidine, Arabinosylcytosine, Cytarabine, Cytosine arabinoside
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C9H13N3O5
CAS Number:
Molecular Weight:
243.22
EC Number:
205-705-9
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
89175
MDL number:
Assay:
90%
grade
reagent grade
product line
Vetec™
assay
90%
storage temp.
2-8°C
SMILES string
NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O
InChI
1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChI key
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
Gene Information
Biochem/physiol Actions
Ara-C incorporates into DNA and inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation; does not inhibit RNA synthesis. Anti-leukemia agent.
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Muta. 1B - Repr. 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bhupender S Chhikara et al.
Expert opinion on drug delivery, 7(12), 1399-1414 (2010-10-23)
Cytarabine is a polar nucleoside drug used for the treatment of myeloid leukemia and non-Hodgkin's lymphoma. The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus
M Low et al.
Internal medicine journal, 43(3), 294-297 (2012-07-05)
Although induction chemotherapy comprising high-dose cytarabine (HiDAC) in combination with idarubicin and etoposide or 'ICE' for adult acute myeloid leukaemia (AML) produces a complete remission rate of nearly 80%, gastrointestinal toxicity is significant. Omission of etoposide may produce similar clinical
Jorge E Romaguera et al.
British journal of haematology, 150(2), 200-208 (2010-06-10)
Mantle cell lymphoma (MCL) has a poor overall survival after treatment with conventional chemotherapy. Intense chemoimmunotherapy without consolidation stem cell transplantation is a potential therapeutic option. We report on a prospective Phase II study with rituximab in combination with fractionated
Global Trade Item Number
| SKU | GTIN |
|---|---|
| V900339-1G | 04061826740019 |